Boston Scientific (NYSE:BSX) Releases Quarterly Earnings Results

Boston Scientific (NYSE:BSX) issued its quarterly earnings data on Wednesday. The medical equipment provider reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.05, Zacks reports. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. Boston Scientific updated its Q1 2025 guidance to 0.660-0.680 EPS and its FY 2025 guidance to 2.800-2.870 EPS.

Boston Scientific Stock Up 1.8 %

BSX stock traded up $1.87 during trading on Wednesday, reaching $105.41. The stock had a trading volume of 3,012,969 shares, compared to its average volume of 5,940,999. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $155.36 billion, a price-to-earnings ratio of 87.12, a P/E/G ratio of 2.68 and a beta of 0.80. Boston Scientific has a one year low of $64.08 and a one year high of $107.17. The company’s 50 day moving average is $94.01 and its two-hundred day moving average is $86.71.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on BSX shares. Canaccord Genuity Group raised their price objective on shares of Boston Scientific from $98.00 to $101.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. StockNews.com upgraded Boston Scientific from a “hold” rating to a “buy” rating in a research note on Wednesday, January 29th. Sanford C. Bernstein lifted their target price on Boston Scientific from $92.00 to $100.00 and gave the stock an “outperform” rating in a report on Thursday, October 24th. Bank of America raised their price target on shares of Boston Scientific from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, October 22nd. Finally, Needham & Company LLC reissued a “hold” rating on shares of Boston Scientific in a report on Wednesday, November 27th. One equities research analyst has rated the stock with a hold rating, twenty-two have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $100.39.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 14,010 shares of the firm’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $89.27, for a total value of $1,250,672.70. Following the completion of the sale, the executive vice president now directly owns 978 shares of the company’s stock, valued at $87,306.06. This trade represents a 93.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $90.78, for a total value of $633,916.74. Following the completion of the sale, the executive vice president now directly owns 29,308 shares of the company’s stock, valued at approximately $2,660,580.24. This trade represents a 19.24 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 47,302 shares of company stock worth $4,464,725 in the last 90 days. Insiders own 0.50% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.